<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE nitf SYSTEM "http://www.nitf.org/IPTC/NITF/3.3/specification/dtd/nitf-3-3.dtd">
<nitf change.date="June 10, 2005" change.time="19:30" version="-//IPTC//DTD NITF 3.3//EN">
  <head>
    <title>Drug Accounts In the Spotlight</title>
    <meta content="MB004627" name="slug"/>
    <meta content="19" name="publication_day_of_month"/>
    <meta content="9" name="publication_month"/>
    <meta content="2000" name="publication_year"/>
    <meta content="Tuesday" name="publication_day_of_week"/>
    <meta content="Business/Financial Desk" name="dsk"/>
    <meta content="10" name="print_page_number"/>
    <meta content="C" name="print_section"/>
    <meta content="4" name="print_column"/>
    <meta content="Health; Business" name="online_sections"/>
    <docdata>
      <doc-id id-string="1231904"/>
      <doc.copyright holder="The New York Times" year="2000"/>
      <series series.name="THE MEDIA BUSINESS: ADVERTISING -- ADDENDA"/>
      <identified-content>
        <classifier class="indexing_service" type="descriptor">Drugs (Pharmaceuticals)</classifier>
        <classifier class="indexing_service" type="descriptor">Lipitor (Drug)</classifier>
        <classifier class="indexing_service" type="descriptor">Heart</classifier>
        <classifier class="indexing_service" type="descriptor">Cholesterol</classifier>
        <classifier class="indexing_service" type="descriptor">Altace (Drug)</classifier>
        <classifier class="indexing_service" type="descriptor">Blood Pressure</classifier>
        <classifier class="indexing_service" type="descriptor">Advertising</classifier>
        <org class="indexing_service">Pfizer Inc</org>
        <org class="indexing_service">Bates Worldwide</org>
        <org class="indexing_service">Wyeth-Ayerst Laboratories</org>
        <org class="indexing_service">Monarch Pharmaceuticals</org>
        <person class="indexing_service">Elliott, Stuart</person>
        <object.title class="indexing_service">Advertising (Times Column)</object.title>
        <classifier class="online_producer" type="taxonomic_classifier">Top/News/Business/Columns/Addenda</classifier>
        <classifier class="online_producer" type="taxonomic_classifier">Top/News/Business</classifier>
        <classifier class="online_producer" type="taxonomic_classifier">Top/News/Business/Media and Advertising</classifier>
        <classifier class="online_producer" type="taxonomic_classifier">Top/News</classifier>
        <classifier class="online_producer" type="taxonomic_classifier">Top/News/Health/Diseases, Conditions, and Health Topics/Cholesterol</classifier>
        <classifier class="online_producer" type="taxonomic_classifier">Top/News/Health/Diseases, Conditions, and Health Topics/Drugs (Pharmaceuticals)/Lipitor (Drug)</classifier>
        <classifier class="online_producer" type="taxonomic_classifier">Top/News/Health/Diseases, Conditions, and Health Topics/Drugs (Pharmaceuticals)</classifier>
        <classifier class="online_producer" type="taxonomic_classifier">Top/News/Health</classifier>
        <classifier class="online_producer" type="taxonomic_classifier">Top/News/Health/Diseases, Conditions, and Health Topics/Heart Disease</classifier>
        <classifier class="online_producer" type="taxonomic_classifier">Top/Classifieds/Job Market/Job Categories/Pharmaceutical, Biotechnology and Science</classifier>
        <classifier class="online_producer" type="taxonomic_classifier">Top/News/Health/Diseases, Conditions, and Health Topics/Blood Pressure</classifier>
        <classifier class="online_producer" type="taxonomic_classifier">Top/Classifieds/Job Market/Job Categories/Marketing, Advertising and PR</classifier>
        <classifier class="online_producer" type="general_descriptor">Cholesterol</classifier>
        <classifier class="online_producer" type="general_descriptor">Blood</classifier>
        <classifier class="online_producer" type="general_descriptor">Blood Pressure</classifier>
        <classifier class="online_producer" type="general_descriptor">Anatomy and Physiology</classifier>
        <classifier class="online_producer" type="general_descriptor">Drugs (Pharmaceuticals)</classifier>
        <classifier class="online_producer" type="general_descriptor">Advertising and Marketing</classifier>
        <classifier class="online_producer" type="general_descriptor">Medicine and Health</classifier>
      </identified-content>
    </docdata>
    <pubdata date.publication="20000919T000000" ex-ref="http://query.nytimes.com/gst/fullpage.html?res=9E03E6DB143BF93AA2575AC0A9669C8B63" item-length="145" name="The New York Times" unit-of-measure="word"/>
  </head>
  <body>
    <body.head>
      <hedline>
        <hl1>Drug Accounts In the Spotlight</hl1>
      </hedline>
      <byline class="print_byline">By Stuart Elliott</byline>
      <byline class="normalized_byline">Elliott, Stuart</byline>
      <abstract>
        <p>Pfizer Inc places in review creative advertising duties for Lipitor, prescription drug to fight high cholesterol, which Bates Worldwide has handled since April 1998; billings estimated at $50 million; Bates is being awarded creative duties for Altace, drug to treat high blood pressure that is joint venture between Wyeth-Ayerst and Monarch Pharmaceuticals; billings estimated at $35 million to $40 million (S)</p>
      </abstract>
    </body.head>
    <body.content>
      <block class="lead_paragraph">
        <p>Drug accounts are coming and going at Bates Worldwide in New York, part of the Cordiant Communications Group.</p>
        <p>Pfizer in New York placed in review the creative duties for Lipitor, a prescription drug to fight high cholesterol, which Bates had handled since April 1998. Billings were estimated at $50 million. Bates decided not to participate in the review.</p>
      </block>
      <block class="full_text">
        <p>Drug accounts are coming and going at Bates Worldwide in New York, part of the Cordiant Communications Group.</p>
        <p>Pfizer in New York placed in review the creative duties for Lipitor, a prescription drug to fight high cholesterol, which Bates had handled since April 1998. Billings were estimated at $50 million. Bates decided not to participate in the review.</p>
        <p>Bates is being awarded creative duties for Altace, a drug to treat high blood pressure that is a joint venture between Wyeth-Ayerst in St. Davids, Pa., which is part of the American Home Products Corporation, and Monarch Pharmaceuticals in Bristol, Tenn., which is part of King Pharmaceuticals. Billings were estimated at $35 million to $40 million. The decision came after a three-month review.</p>
        <p>THE MEDIA BUSINESS: ADVERTISING -- ADDENDA</p>
      </block>
    </body.content>
  </body>
</nitf>
